Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 31, Issue 12, 2013, Pages

  Klein, Oliver ^a   Ribas, Antoni ^b,c   Chmielowski, Bartosz ^b,c   Walker, Grant ^a   Clements, Arthur ^a   Long, Georgina V ^a,d   Kefford, Richard F ^a,d  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DACARBAZINE; HMB 45 ANTIGEN; PREDNISONE; PROTEIN S 100; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VEMURAFENIB;

ADULT; ANALGESIA; ARTICLE; AXILLA METASTASIS; AXILLARY LYMPH NODE; AXILLARY METASTASIS; BELL PALSY; BONE METASTASIS; CALCANEUS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DELTOID MUSCLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FACIAL NERVE; FEMORAL METASTASIS; FEMUR; FOLLOW UP; FOOT AMPUTATION; GENE MUTATION; HEART METASTASIS; HEART RIGHT ATRIUM; HUMAN; LYMPH NODE METASTASIS; MALE; MEDIASTINUM; METASTASIS; METASTATIC MELANOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; VISUAL IMPAIRMENT;

ANTINEOPLASTIC AGENTS, HORMONAL; FACIAL PARALYSIS; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; PREDNISONE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84876583493     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.7028     Document Type: Article

References (11)

1. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
2. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507- 2516, 2011
3. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
4. Su F, Viros A, Milagre C, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215, 2012
5. Oberholzer PA, Kee D, Dziunycz P, et al: RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-321, 2012
6. Gilden DH: Clinical practice: Bell's palsy. N Engl J Med 351:1323-1331, 2004
7. Sullivan FM, Swan IR, Donnan PT, et al: Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 357:1598-1607, 2007 (Pubitemid 47598402)
8. Wisler JA, Afshari C, Fielden M, et al: Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat. Toxicol Pathol 39:809-822, 2011
9. Rakhra K, Bachireddy P, Zabuawala T, et al: CD4(-) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18:485-498, 2010
10. Balachandran VP, Cavnar MJ, Zeng S, et al: Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17:1094-1100, 2011
11. Wilmott JS, Long GV, Howle JR, et al: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386-1394, 2012